CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies
Go back to CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies| (NASDAQ: CRSP) | Delayed: 54.36 +0.27 (0.50%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $54.09 | 52 Week High | $18.88 | |||
| Open | $54.85 | 52 Week Low | $13.75 | |||
| Day High | $56.08 | P/E | N/A | |||
| Day Low | $54.08 | EPS | $0.00 | |||
| Volume | 1,135,624 | |||||
| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 466.79 +15.16 (3.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $451.63 | 52 Week High | $134.71 | |||
| Open | $455.65 | 52 Week Low | $73.31 | |||
| Day High | $468.18 | P/E | N/A | |||
| Day Low | $453.21 | EPS | $-1.98 | |||
| Volume | 2,034,572 | |||||
